Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 3.2.2025Sandoz Pharmaceuticals d.d. (SAN-SLO-4)90197Aclasta 5 mg infúzny roztok (sol inf 1x100 ml/5 mg (fľ.plast.))31.1.2025R
 3.2.2025Sandoz Pharmaceuticals d.d. (SAN-SLO-1)99949Ciprofloxacín Sandoz 500 mg filmom obalené tablety (tbl flm 20x500 mg (blis.PP/Al))31.1.2025R
 3.2.2025B.Braun Melsungen AG (BME)41819Lipoplus 20 % (emu inf 10x250 ml (fľ.skl.))4.2.2025R
 3.2.2025STADA Arzneimittel AG (STD)3646ELosartan STADA Arzneimittel 50 mg filmom obalené tablety (tbl flm 30x50 mg (blis.PVC/PE/PVDC/Al))10.9.2024U
 3.2.2025STADA Arzneimittel AG (STD)3648ELosartan STADA Arzneimittel 50 mg filmom obalené tablety (tbl flm 90x50 mg (blis.PVC/PE/PVDC/Al))20.6.2024U
 3.2.2025STADA Arzneimittel AG (STD)4205ELosartan/Hydrochlorothiazide STADA Arzneimittel 50 mg/12,5 mg (tbl flm 30x50 mg/12,5 mg (blis.PVC/PE/PVDC/Al))25.9.2024U
 3.2.2025STADA Arzneimittel AG (STD)4207ELosartan/Hydrochlorothiazide STADA Arzneimittel 50 mg/12,5 mg (tbl flm 90x50 mg/12,5 mg (blis.PVC/PE/PVDC/Al))25.9.2024U
 3.2.2025STADA Arzneimittel AG (STD)4219ELosartan/Hydrochlorothiazide STADA Arzneimittel 100 mg/25 mg (tbl flm 30x100 mg/25 mg (blis.PVC/PE/PVDC/Al))31.1.2025U
 3.2.2025STADA Arzneimittel AG (STD)4222ELosartan/Hydrochlorothiazide STADA Arzneimittel 100 mg/25 mg (tbl flm 98x100 mg/25 mg (blis.PVC/PE/PVDC/Al))31.1.2025U
 3.2.2025B.Braun Melsungen AG (BME)5716ARingerfundin (sol inf 10x500 ml (fľ.PE))3.2.2025O
 3.2.2025B.Braun Melsungen AG (BME)76566Metronidazol B. Braun 5 mg/ml (sol inf 20x100 ml/500 mg (fľ. PE))3.2.2025O
 3.2.2025B.Braun Melsungen AG (BME)5006BAqua pro injectione Braun (lif par 20x100 ml (fľ.LDPE))3.2.2025O
 3.2.2025B.Braun Melsungen AG (BME)1344CNutriflex Omega special 56/144 (emu inf 5x1250 ml (vak infúzny viackomorový))3.2.2025O
 3.2.2025Instituto Grifols, S.A. (GFO)9511DXembify 200 mg/ml roztok na subkutánnu injekciu (sol icu 1x10 ml/2 g (liek.inj.skl.))29.1.2025U
 31.1.2025Takeda Manufacturing Austria AG (TKM-5)20049KIOVIG 100 mg/ml infúzny intravenózny roztok (sol inf 1x300 ml/30 g (liek.inj.skl.))31.1.2025R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)